WuXi BioInnovate
Luncheon Series
.png)
Concept
Join Us!
Join us for the WuXi BioInnovate Luncheon Series at Biologics Manufacturing Asia 2025, where industry leaders come together for a dynamic and interactive discussion on overcoming the toughest challenges in biologics manufacturing. This exclusive session is designed to explore how WuXi Biologics collaborates with partners to navigate complexities at every stage of production, setting the benchmark for a successful CDMO-client partnership. Engage with industry experts, gain fresh insights from real-world case studies, and participate in expert-led panel discussions that tackle practical problems head-on. This is more than just a luncheon—it’s a platform for idea exchange, problem-solving, and driving the future of biologics manufacturing forward.
Highlights
- Gain valuable insights and explore practical applications through scientific talks.
- Explore cutting-edge solutions at our product demonstrations and exhibition.
- Connect & engage with industry experts and peers to discuss innovative strategies for utilizing Sartorius' solutions.
Sessions
Agenda
Registration & Guest Ushering
Pooja Zaveri & IMAPAC
Time : 12:30 - 12:45
Registration & Guest Ushering
Pooja Zaveri & IMAPAC
Opening Speech
Shine Huang, Head, Global Marketing, WuXi Biologics, China
Strategies and Innovations to Accelerate Biologics Development
Hang Zhou, Senior Vice President & Head, Bioprocess Research & Development, WuXi Biologics, China
Overcoming CMC and Assay Bottlenecks
Facilitator :
Dr. Hu Jun, Head of Client Enabling Center of Excellence & Head of Singapore Site Management, WuXi Biologics, China
Speakers :
Yuan Wen, Vice President, Global Manufacturing Business Unit, WuXi Biologics, China
Gary Khoo, VP of Chemistry, Manufacturing & Controls (CMC), Hummingbird Bioscience, Singapore
Bin Zhou, Chief Executive Office, Axcynsis Therapeutics, Singapore
Veronica Diermayr, Director, Asset Lead, Experimental Drug Development Centre (EDDC), Singapore
Luncheon Closing Remarks
Shine Huang, Head, Global Marketing, WuXi Biologics, China
Esteemed Voices From the Industry
Our selected experts will share insights on the latest trends, challenges, and developments in this dynamic field. Engage in unique discussions, learn about cutting-edge scientific discoveries, and explore the future of biopharmaceuticals with these influential thought leaders.
Dr. Yuan Wen is currently focused on key account business development, and served as head of MFG1, MFG4, and later Zhejiang Site (MFG20 and DP9) of Global Manufacturing in WuXi Biologics. His teams were the first in Asia to implement 4000L and 5000L single-use bioreactors in GMP and commercial manufacturing, serving global clients for products approved by FDA, EMA, and NMPA etc. Prior to his roles in MFG, he was responsible for CCPD at the Wuxi site, focusing on late phase development and process characterization. Dr. Wen is also an experienced CMC leader to support activities from IND to commercial manufacturing. Before joining WuXi Biologics, he worked at Life Technologies and Thermo Fisher Scientific in the US, with increasing technical and business responsibilities. He holds a B.S. degree in Bioengineering from Zhejiang University, and a Ph.D. degree in Chemical and Biomolecular Engineering from The Ohio State University.
Gary Khoo is the Head of CMC at Hummingbird Bioscience, where he oversees process and analytical development, as well as CMC operations and strategy for a portfolio of antibody-based therapies, including antibody-drug conjugates (ADCs). He holds a Ph.D. in Biochemical Engineering from the University of Birmingham, UK, and brings over 20 years of experience across drug development, CMC, and manufacturing. Dr. Khoo’s expertise encompasses a wide range of modalities—recombinant proteins, monoclonal antibodies, viral vectors and vaccines, and cell- and gene-therapy products—spanning all stages of the product lifecycle from IND enabling studies, BLA process validation to commercial manufacturing.
